KNT-0916
/ KinoTeck Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2026
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
(clinicaltrials.gov)
- P1 | N=151 | Recruiting | Sponsor: KinoTeck Therapeutics Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor • FGFR2
1 to 1
Of
1
Go to page
1